Meta AnalysisID 4045
氯丙嗪对比利血平治疗精神分裂症 [Cochrane方案]
CRD42016045566
To investigate the effects of an old and outdated medication (reserpine) in comparison to one that has stood the test of time (chlorpromazine) for people with schizophrenia.
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Ingredient: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 4045
- Evidence Id
- 12603
- Core Evidence Id
- 12603
- Source Meta Analysis Id
- 4005
- Herb2 Meta Analysis Id
- HBMA004005
- Crd Id
- CRD42016045566
- Title
- Chlorpromazine versus reserpine for schizophrenia [Cochrane Protocol]
- Review Question
- To investigate the effects of an old and outdated medication (reserpine) in comparison to one that has stood the test of time (chlorpromazine) for people with schizophrenia.
- Study Type Included
- All relevant randomised controlled trials. If a trial is described as 'double blind' but implies randomisation, we will include such trials in a sensitivity analysis (see Sensitivity analysis). We will exclude quasi-randomised studies, such as those allocating by alternate days of the week. Where people are given additional treatments within the chlorpromazine or reserpine groups, we will only include data if the adjunct treatment is evenly distributed between groups and it is only the chlorpromazine or reserpine group that is randomised.
- Condition Being Studied
- The Cochrane Schizophrenia Group
- Participant
- Adults, however defined, with schizophrenia or related disorders, including schizophreniform disorder, schizoaffective disorder and delusional disorder, again, by any means of diagnosis. We are interested in making sure that information is as relevant to the current care of people with schizophrenia as possible so propose, if information is available, to clearly highlight the current clinical state (acute, early post-acute, partial remission, remission) as well as the stage (prodromal, first episode, early illness, persistent), and as to whether the studies primarily focused on people with particular problems (for example, negative symptoms, treatment-resistant illnesses).
- Animal
- Human Disease Modelled
- Intervention
- 1. Chlorpromazine Any dose or means of delivery. 2. Reserpine Any dose or means of delivery.
- Comparator Control
- Chlorpromazine (any dose or means of delivery) versus reserpine (any dose or means of delivery).
- Main Outcome
- 1. Global state 1.1 Global improvement - to a clinically important extent (defined by each study). 2. Mental state 2.1 Positive symptoms - clinically important improvement - psychological improvement 3. Functioning 3.1 Self-care - improved to a clinically important extent (defined by each study). 4. Adverse effects 4.1 Specific - important adverse effect
- Outcome Measure
- Additional Outcome
- 1. Global state 1.1 Length of hospital stay 1.2 Illness status (binary or continuous data) 2. Mental state 2.1 General symptoms (binary or continuous data) 2.2 Specific symptoms (binary or continuous data) 2.2.1 Positive symptoms (delusions, hallucinations) 2.2.2 Negative symptoms (lack of emotion, lack and apathetic appearance) 3. Leaving the study early 3.1 For any reason 3.2 Due to adverse effects 3.3 Due to loss to follow-up 3.4 Due to acceptability of treatment 4. Behaviour and social functioning 4.1 General behaviour (binary or continuous data) 4.2 Important change in behaviour 4.3 Incidence of violence (self-violence, violence to others) 4.4 Adherence to the appropriate treatment 4.5 Social functioning (binary or continuous data) 4.5.1 Employment status (employed/unemployed) 4.5.2 Accommodation status 4.5.3 Alcohol use 4.5.4 Drug use 5. Quality of life 5.1 Important change in quality of life 5.2 General quality of life (binary or continuous data) 6. Adverse effects 5.1 General (binary or continuous data) 5.2 Specific (binary or continuous data) 'Summary of findings' tables We will use the GRADE approach to interpret findings (Schünemann 2008) and will use GRADE profiler (GRADEPRO) to import data from RevMan 5 (Review Manager) to create 'Summary of findings' tables. These tables provide outcome-specific information concerning the overall quality of evidence from each included study in the comparison, the magnitude of effect of the interventions examined, and the sum of available data on all outcomes we rate as important to patient-care and decision making. We aim to select the following main outcomes for inclusion in the 'Summary of findings' tables.<ol> Global state: Global improvement - to an important extent Mental state: Positive symptoms - clinically important improvement - psychological improvement Functioning - self-care improved Leaving the study early - due to adverse effects Behaviour: important change Quality of life - important change Adverse effects - important adverse effects</ol>
- Study Method
- Intervention, Systematic review
- Keyword
- Antipsychotic Agents; Chlorpromazine; Drug Therapy; Humans; Reserpine; Schizophrenia; Treatment Outcome
- Contact
- Selin Nur [email protected]
- Organisational Affiliation
- The Cochrane Collaboration http://www.cochrane.org/
- Funding Source
- Hochschule Neu-Ulm, University of Nottingham, Hochschule Ulm, Hochschule Neu-Ulm, University of Nottingham, Hochschule Ulm
- Other Selection Criteria
- Final Publication
- Same Topic Review
- Published Protocol
- Review Type
- Language
- English
- Country
- England, Germany
- Review Stage
- Review Ongoing
- First Submission Date
- Registration Date
- 2016-08-09
- Anticipated Start Date
- 2016-03-15
- Anticipated Completion Date
- 2016-05-20
- Title Cn
- 氯丙嗪对比利血平治疗精神分裂症 [Cochrane方案]
- Title En
- Chlorpromazine versus reserpine for schizophrenia [Cochrane Protocol]
- Bilingual Status
- complete